These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 8382551)

  • 1. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
    Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
    Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
    Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
    Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
    Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
    Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
    Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line.
    Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1987 Apr; 47(7):1780-4. PubMed ID: 3028613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
    Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.